DEPLETION OF CIRCULATING CYST(E)INE BY ORAL AND INTRAVENOUS MESNA

被引:30
作者
STOFERVOGEL, B
CERNY, T
KUPFER, A
JUNKER, E
LAUTERBURG, BH
机构
[1] UNIV BERN,DEPT CLIN PHARMACOL,MURTENSTR 35,CH-3010 BERN,SWITZERLAND
[2] INSELSPITAL BERN,INST MED ONCOL,CH-3010 BERN,SWITZERLAND
关键词
D O I
10.1038/bjc.1993.391
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The sulfhydryl status of normal and tumour cells is critically important in determining their susceptibility to various cytostatic agents. As a sulfhydryl compound, mesna (sodium 2-mercaptoethane-sulfonate) which is used in large doses to prevent haemorrhagic cystitis associated with certain chemotherapeutic regimens might derange cellular thiol homeostasis. In order to investigate the effects of mesna on the concentrations of thiols in plasma, cysteine, glutathione and their disulfides were measured by HPLC following the oral and intravenous administration of mesna to healthy volunteers. After 7.3 mmol mesna i.v. free cysteine rose from 8.2 (95% CI 7.0-9.4) nmol ml-1 to 53.6 (47.4-59.8) nmol ml-1 at 5 min, most likely due to reduction of circulating cystine by the sulfhydryl drug. This initial rise was followed by a marked decrease of total cyst(e)ine in plasma from 276 (215-337) nmol ml-1 to a nadir of 102 (89-115) nmol ml-1 between 30-120 min after infusion, most likely due to an increased uptake of cysteine into cells and an increased urinary excretion of cyst(e)ine. Qualitatively similar changes were seen after oral mesna. The present data indicate that mesna depletes circulating cyst(e)ine and may thereby markedly alter the sulfhydryl status of cells in vivo although the drug itself is not taken up by most cells.
引用
收藏
页码:590 / 593
页数:4
相关论文
共 14 条
[1]   DIVERGENT EFFECTS OF INTRAVENOUS GSH AND CYSTEINE ON RENAL AND HEPATIC GSH [J].
AEBI, S ;
LAUTERBURG, BH .
AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 263 (02) :R348-R352
[2]   HIGH-DOSE INTRAVENOUS GLUTATHIONE IN MAN - PHARMACOKINETICS AND EFFECTS ON CYST(E)INE IN PLASMA AND URINE [J].
AEBI, S ;
ASSERETO, R ;
LAUTERBURG, BH .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1991, 21 (01) :103-110
[3]  
Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9
[4]   IFOSFAMIDE MESNA - A REVIEW OF ITS ANTINEOPLASTIC ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN CANCER [J].
DECHANT, KL ;
BROGDEN, RN ;
PILKINGTON, T ;
FAULDS, D .
DRUGS, 1991, 42 (03) :428-467
[5]   GLUTATHIONE DEPLETION IN HIV-INFECTED PATIENTS - ROLE OF CYSTEINE DEFICIENCY AND EFFECT OF ORAL N-ACETYLCYSTEINE [J].
DEQUAY, B ;
MALINVERNI, R ;
LAUTERBURG, BH .
AIDS, 1992, 6 (08) :815-819
[6]   2-MERCAPTOETHANESULFONATE-CYSTEINE DISULFIDE EXCRETION FOLLOWING THE ADMINISTRATION OF 2-MERCAPTOETHANESULFONATE - A PITFALL IN THE DIAGNOSIS OF SULFITE OXIDASE DEFICIENCY [J].
DURAN, M ;
AARSEN, G ;
FOKKENS, RH ;
NIBBERING, NMM ;
CATS, BP ;
DEBREE, PK ;
WADMAN, SK .
CLINICA CHIMICA ACTA, 1981, 111 (01) :47-53
[7]   PROMOTION OF CYSTINE UPTAKE AND ITS UTILIZATION FOR GLUTATHIONE BIOSYNTHESIS INDUCED BY CYSTEAMINE AND N-ACETYLCYSTEINE [J].
ISSELS, RD ;
NAGELE, A ;
ECKERT, KG ;
WILMANNS, W .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (05) :881-888
[8]   PHARMACOKINETICS OF INTRAVENOUS AND ORAL SODIUM 2-MERCAPTOETHANE SULFONATE (MESNA) IN NORMAL SUBJECTS [J].
JAMES, CA ;
MANT, TGK ;
ROGERS, HJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (05) :561-568
[9]   EXCRETION OF SODIUM 2-MERCAPTOETHANESULPHONATE (MESNA) IN THE URINE OF VOLUNTEERS AFTER ORAL DOSING [J].
JONES, MS ;
MURRELL, RD ;
SHAW, IC .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (05) :553-555
[10]  
LAUTERBURG BH, 1984, J PHARMACOL EXP THER, V230, P7